Sunday, October 09, 2022 4:31:21 PM
:) Rubberneck2
Ps. Data coming soon as all us longs know.
Pps. wtf this guy means by crossing eyes :)
Ps. Data coming soon as all us longs know.
Pps. wtf this guy means by crossing eyes :)
Really hoping the can close the down on new endpoint standards with the FDA. That would create a lot of momentum going into the DSMB meeting, where unblinded trial data to them will take precedence. Inflection point upcoming.
— The Dales Report (@TheDalesReport) October 8, 2022
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
